SCHEMBL2289653

SCHEMBL2289653

CNC(=O)COc1ccccc1-c1nc2ccccn2c1Nc1c(C)cccc1C

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 12/20 0.53
MAPT P10636 12/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
HTT P42858 2/20 0.53
KMT2A Q03164 2/20 0.53
MAPK1 P28482 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TP53 P04637 8/20 0.50
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GFER P55789 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 1/20 0.41
PKM P14618 1/20 0.40
PKLR P30613 1/20 0.40
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288504 0.89 GAA (0.54) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2290103 0.88 GAA (0.43) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2289978 0.88 GAA (0.53) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2295279 0.84 GAA (0.48) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2287194 0.84 GAA (0.53) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2290892 0.83 GAA (0.49) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2291064 0.82 GAA (0.54) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2292757 0.82 GAA (0.46) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2292520 0.82 GAA (0.45) GAAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL2288909 0.81 GAA (0.49) GAAMAPTSMN1; SMN2HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.